tiprankstipranks
Intensity Therapeutics announces first dosing in Phase 2 trial of INT230-6
PremiumThe FlyIntensity Therapeutics announces first dosing in Phase 2 trial of INT230-6
2M ago
Intensity Therapeutics initiated with a Buy at H.C. Wainwright
Premium
The Fly
Intensity Therapeutics initiated with a Buy at H.C. Wainwright
2M ago
Intensity Therapeutics Shareholders Engage and Elect at Annual Meeting
Premium
Company Announcements
Intensity Therapeutics Shareholders Engage and Elect at Annual Meeting
5M ago
Intensity Therapeutics, The Swiss Group sign collaboration agreement
PremiumThe FlyIntensity Therapeutics, The Swiss Group sign collaboration agreement
8M ago
Intensity Therapeutics reports Q1 EPS (34c) vs. (39c) last year
Premium
The Fly
Intensity Therapeutics reports Q1 EPS (34c) vs. (39c) last year
8M ago
Portage Biotech completes monetization of  Intensity Therapeutics shares
Premium
The Fly
Portage Biotech completes monetization of Intensity Therapeutics shares
9M ago
Intensity Therapeutics names Joseph Talamo as CFO
PremiumThe FlyIntensity Therapeutics names Joseph Talamo as CFO
1y ago
Intensity Therapeutics reports results from Phase 2 INVINCIBLE trial of INT230-6
Premium
The Fly
Intensity Therapeutics reports results from Phase 2 INVINCIBLE trial of INT230-6
1y ago
Intensity Therapeutics reports Q3 EPS (17c) vs (52c) last year
Premium
The Fly
Intensity Therapeutics reports Q3 EPS (17c) vs (52c) last year
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100